Case series: Brolucizumab efficacy and safety in treating neovascular age-related macular degeneration

Linling Cheng; Charlotte L. Zhang; Cheryl C. Lai; Ning Sun; Hiuwa Hang

doi:10.1002/mef2.70010

MEDCOMM - Future Medicine ›› 2025, Vol. 4 ›› Issue (1) : e70010 DOI: 10.1002/mef2.70010

LETTER

Case series: Brolucizumab efficacy and safety in treating neovascular age-related macular degeneration

Author information +

History +

PDF

Cite this article

Download citation ▾

Linling Cheng, Charlotte L. Zhang, Cheryl C. Lai, Ning Sun, Hiuwa Hang. Case series: Brolucizumab efficacy and safety in treating neovascular age-related macular degeneration. MEDCOMM - Future Medicine, 2025, 4(1): e70010 DOI:10.1002/mef2.70010

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	BhuttoI, LuttyG. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 2012; 33(4):295-317.

[2]	BrownDM, JaffeGJ, WykoffCC, Adiguzel E, HeierJS, KhananiAM. MERLIN: two-year results of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2024.

[3]	BodaghiB, SouiedEH, TadayoniR, Weber M, PonthieuxA, KodjikianL. Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration. Ophthalmol Retina. 2023; 7(10):879-891.

[4]	DugelPU, KohA, OguraY, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020; 127(1):72-84.

[5]	HoshiK, Kunikata H, AizawaN, et al. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. Int Ophthalmol. 2023; 43(12):4701-4709.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).